Drug Trial Radar · NCT03743883
EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom ("ENgAGE - UK"): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK
Last checked: Nov 19, 2026Latest source record: Jun 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99,999
Actual
Start
Oct 30, 2018
Primary completion
Apr 15, 2019
Study completion May 31, 2019
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Nov 16, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers already did studies in low-dose Aspirin for the prevention of heart and blood vessels disease and for the prevention of cancer of the colorectum. In this study, they want to learn whether an effect for the prevention of oesophagus cancer and stomach cancer goes along with the use of low-dose ASA on patients taking this medicine for the prevention of heart and blood vessels disease compared to non-use. To find this out electronic medical records stored in primary care database in the UK, The Health Improvement Network (THIN), will be used.
Conditions
- Prevention of Oesophagus Cancer and Stomach Cancer
Interventions
Acetylsalicylic Acid(BAYE4465, Aspirin )Drug
Administration according to clinical practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA overall compared to non-useTime frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
- Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by age compared to non-useTime frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
- Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-useTime frame: Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Many locations
Multiple Locations, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.